Literature DB >> 15616161

Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer.

Gergely Szakács1, Michael M Gottesman.   

Abstract

Gene expression arrays allow researchers to profile the differences between cell lines or tissues and they may identify genetic markers of development, organ maturation, or tumor progression. Although a primary tumor that grows in a host and a tumor-cell-line derived from that primary tumor and grown in vitro share similar gene expression profiles, there are, not unexpectedly, some important differences. In fact, Stein and colleagues have found that genes that are differentially expressed in primary tumors as compared to the specific genes expressed in their cell-line derivatives are more reliably predictive of tumor tractability. Thus, sensitivity in vitro might not reflect sensitivity in vivo. Because anti-tumor compounds are largely evaluated in cell culture assays, these compounds' therapeutic utility must be judged in light of genes described by Stein et al. that better predict tractability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15616161     DOI: 10.1124/mi.4.6.5

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  8 in total

Review 1.  Preclinical development of molecular-targeted agents for cancer.

Authors:  Alberto Ocana; Atanasio Pandiella; Lillian L Siu; Ian F Tannock
Journal:  Nat Rev Clin Oncol       Date:  2010-12-07       Impact factor: 66.675

Review 2.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

3.  Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy.

Authors:  Pawel Mroz; Ying-Ying Huang; Angelika Szokalska; Timur Zhiyentayev; Sahar Janjua; Artemissia-Phoebe Nifli; Margaret E Sherwood; Christian Ruzié; K Eszter Borbas; Dazhong Fan; Michael Krayer; Thiagarajan Balasubramanian; Eunkyung Yang; Hooi Ling Kee; Christine Kirmaier; James R Diers; David F Bocian; Dewey Holten; Jonathan S Lindsey; Michael R Hamblin
Journal:  FASEB J       Date:  2010-04-12       Impact factor: 5.191

4.  Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.

Authors:  Gregory Lucien Bellot; Wei Han Tan; Ling Lee Tay; Dean Koh; Xueying Wang
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-21       Impact factor: 4.553

5.  The evolution of single cell-derived colorectal cancer cell lines is dominated by the continued selection of tumor-specific genomic imbalances, despite random chromosomal instability.

Authors:  Darawalee Wangsa; Rüdiger Braun; Madison Schiefer; Edward Michael Gertz; Daniel Bronder; Isabel Quintanilla; Hesed M Padilla-Nash; Irianna Torres; Cynthia Hunn; Lidia Warner; Floryne O Buishand; Yue Hu; Daniela Hirsch; Timo Gaiser; Jordi Camps; Russell Schwartz; Alejandro A Schäffer; Kerstin Heselmeyer-Haddad; Thomas Ried
Journal:  Carcinogenesis       Date:  2018-07-30       Impact factor: 4.944

6.  Trafficking microenvironmental pHs of polycationic gene vectors in drug-sensitive and multidrug-resistant MCF7 breast cancer cells.

Authors:  Han Chang Kang; Olga Samsonova; You Han Bae
Journal:  Biomaterials       Date:  2010-01-21       Impact factor: 12.479

Review 7.  Contemporary murine models in preclinical astrocytoma drug development.

Authors:  Robert S McNeill; Mark Vitucci; Jing Wu; C Ryan Miller
Journal:  Neuro Oncol       Date:  2014-09-21       Impact factor: 12.300

Review 8.  Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.

Authors:  Gergely Szakács; Matthew D Hall; Michael M Gottesman; Ahcène Boumendjel; Remy Kachadourian; Brian J Day; Hélène Baubichon-Cortay; Attilio Di Pietro
Journal:  Chem Rev       Date:  2014-04-23       Impact factor: 60.622

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.